BLS Pharmaceuticals Limited (ASX:BLS) Targets FY27 Growth Through Manufacturing Expansion

Aditi Sarkar

11 November 2026 04:33 PM AEDT

BLS Pharmaceuticals Limited (ASX:BLS) Targets FY27 Growth Through Manufacturing Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• BLS reported September-quarter Revenue of AUD 26.7 million, rising 23% from the preceding quarter in FY27.

• The company generated AUD 2.0 million in positive Operating Cash Flow during the first quarter of FY27.

• Manufacturing Investment included AUD 2.4 million in Scotland and AUD 0.3 million across Australian sites during the quarter.

• BLS reaffirmed its FY27 revenue guidance of AUD 105 million to AUD 115 million after the quarterly update.

Quarterly sales growth has shifted attention to manufacturing capacity at BLS Pharmaceuticals Limited (ASX:BLS). The pharmaceutical group reported a stronger September quarter and reaffirmed its FY27 guidance while continuing investment in its production sites.

Market Activity

BLS Pharmaceuticals was trading around 95 cents at about 2:40pm AEDT on 11 November 2026, up roughly 3.3% on the previous close, on Volume of about 139,000 shares. That is well below the stock’s Average Daily Volume of around 307,000 shares, so this is a modest move on light trade. No announcement had been lodged with the ASX today, and the company’s most recent filings were routine. The most useful context is therefore the Business update the market has been digesting since October.

Recent Developments

On 21 October 2026 BLS lodged a price-sensitive Q1 FY2027 quarterly activities update. It also reported positive operating cash flow of AUD 2.0 million and held AUD 17.5 million of inventory to support domestic and international Supply commitments. The company attributed the growth to higher manufacturing volumes, expansion in white-label and contract manufacturing, and continued supply to ADREXpharma in Germany. BLS also said it spent AUD 2.4 million on its Scotland Facility and AUD 0.3 million on Australian sites during the quarter. It reaffirmed the FY27 guidance it set on 31 August.

Manufacturing Platform

BLS describes itself as an Australian pharmaceutical company that makes, develops and commercialises regulated therapeutic products and active pharmaceutical ingredients. Its GMP-licensed platform covers manufacturing, import, export and distribution, with a focus on medicinal cannabis, psychedelic-based medicines and other controlled products. BLS has manufacturing agreements with Aurora Cannabis and Curaleaf International and commercial relationships across Europe and Latin America. Its anchor international contract is a two-year, AUD 50 million supply agreement with ADREXpharma in Germany.

Financial Performance

BLS lifted revenue from about AUD 29.3 million in FY25 to AUD 74.2 million in FY26, with Net Income rising from AUD 4.9 million to about AUD 15.4 million. Two years earlier, in FY24, it recorded a loss of about AUD 13.3 million on revenue of AUD 9.7 million, so the turnaround has been rapid. The company’s Market Capitalisation was about AUD 217 million on ASX figures, and the shares have traded between 35 cents and AUD 1.295 over the past 52 weeks. For FY27, BLS has guided to revenue of AUD 105 million to AUD 115 million, which it said represents growth of 42% to 55% on FY26, with an adjusted EBITDA Margin of 23% to 26%.

Industry Setting

The company says the global regulatory environment is becoming more accepting of cannabis, MDMA and psilocybin-based medicines. Demand depends on approvals in each market, and those can shift.

Business Considerations

A large share of recent growth is tied to supply into Germany, so any change to that contract, to German reimbursement settings or to Import rules would matter. Execution on the new Scottish Borders site is another factor. The company has said the GMP production site is under construction and expected to be complete by the end of 2026, but construction timelines and licensing can slip. Inventory of AUD 17.5 million also ties up cash if demand softens.

Next Milestones

The company has not announced a date for its next quarterly report. Its notice of Annual General Meeting was lodged on 23 October. For now, BLS has said it is focused on execution: lifting utilisation of its Australian manufacturing capacity, delivering on existing international contracts and commissioning the Scottish site by the end of 2026.

FAQs

Q: What was quarterly revenue?

A: AUD 26.7 million.

Q: What was quarterly operating cash flow?

A: Positive AUD 2.0 million.

Q: What FY27 revenue does BLS target?

A: AUD 105 million to AUD 115 million.

Q: Which overseas facility is under development?

A: Its Scottish Borders production site.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.